Home
Clinical Trials
Efficacy and Safety Trials of...

Efficacy and Safety Trials of Yangxinshi Tablets in the Treatment of Patients With Coronary Heart Disease Complicated by Cardiac Dysfunction

Last Updated: 2025-11-25

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

RECRUITING

Clinical Phase

PHASE4

Total Enrollment

2708 participants

Study Classification

INTERVENTIONAL

Study Start Date

2025-11-06

Study Completion Date

2030-12-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

A randomized controlled trial was conducted to evaluate the efficacy and safety of Yangxinshi tablets in improving the condition of patients with coronary heart disease complicated by cardiac dysfunction.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Efficacy and Safety of QiShen YiQi Dripping Pills in Chronic Heart Failure

NCT04983043

Chronic Heart Failure With Reduced Ejection Fraction

COMPLETED PHASE2

Efficacy Study of Hydroxychloroquine to Treat High-risk Coronary Artery Disease.

NCT02874287

Coronary Artery Disease

COMPLETED PHASE4

Study of Qiliqiangxin Capsule to Treat Dilated Cardiomyopathy

NCT01293903

Dilated Cardiomyopathy Heart Failure

COMPLETED PHASE4

Pharmacokinetic and Pharmacodynamic of Jia Shen Tablets in Chronic Heart Failure

NCT06348498

Heart Failure

RECRUITING PHASE1

Clinical Study on the Effect of Zhenyuan Capsule on Cardiopulmonary Function in Patients With SCAD

NCT04421287

Stable Coronary Heart Disease

UNKNOWN PHASE4

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

The purpose of this study was to investigate whether the addition of Yangxinshi tablets to conventional treatment can reduce the composite endpoint time, increase exercise tolerance, and improve quality of life and mental health in patients with coronary heart disease complicated by cardiac dysfunction. A total of 2708 eligible patients were randomly divided into two groups. In addition to conventional treatment, the trial group was given Yangxinshi tablets (3 tablets/time, 3 times/day), while the control group was a blank control. The treatment cycle continued until the expected number of endpoint events was reached or the study ended, whichever occurred first. The primary endpoint was the composite endpoint of ischemic events or heart failure-related clinical events (including all-cause death, ischemia-driven revascularization, stroke, myocardial infarction (MI), and readmission due to aggravated ACS or heart failure) during the study period.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Coronary Heart Disease Cardiac Dysfunction

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Trial group

Basic treatment and Trial drug

Group Type EXPERIMENTAL

Yangxinshi tablet

Intervention Type DRUG

Basic treatment: All patients received a conventional treatment regimen, including outcome-improving drugs (aspirin, P2Y12 receptor inhibitor、β-blockers, statins, ARNI /ACEI/ARB, SGLT2i, and MRA) and symptom-relieving drugs (nitrates, calcium antagonists, and loop diuretic).

Trial drug: Yangxinshi tablets, 3 tablets/3 times a day, taken orally

Control group

Basic treatment

Group Type SHAM_COMPARATOR

Blank control

Intervention Type DRUG

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Yangxinshi tablet

Intervention Type DRUG

Blank control

Intervention Type DRUG

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

Yangxinshi

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. For inpatients diagnosed with coronary heart disease (including acute coronary syndrome and chronic coronary syndrome), it is up to the doctor to decide whether to undergo revascularization and what kind of revascularization to use.
2. Patients aged between 40 and 80 years (inclusive), regardless of sex;
3. Patients with NYHA cardiac function classes II-IV;
4. Patients with NT-proBNP \> 125 pg/mL (or BNP\>35 pg/mL);
5. The syndrome differentiation in traditional Chinese medicine conforms to chest obstruction (qi deficiency and blood stasis syndrome)
6. Patients who voluntarily participated and signed an informed consent form.

Exclusion Criteria

1. Patients with STEMI within 3 days;
2. Patients at extremely high risk of NSTEMI (hemodynamic instability, cardiogenic shock, new-onset heart failure or aggravated heart failure, severe ventricular arrhythmia)
3. Patients with acute myocardial infarction complicated with cardiogenic shock, mechanical complications, respiratory failure and other multiple organ failure;
4. Patients with severe liver dysfunction (transaminase levels more than three times the upper limit of normal), renal insufficiency (eGFR \< 30mL/min/1.73m2), acute infectious diseases, and mental disorders;以上翻译结果来自有道神经网络翻译（YNMT）· 通用场景
5. Patients with drug-resistant hypertension (systolic blood pressure ≥180 mmHg and/or diastolic blood pressure ≥110 mmHg);
6. Pregnant or lactating women, or those planning pregnancy during the study period;
7. Patients who cannot tolerate 3 months of dual antiplatelet therapy;
8. Patients with allergic reactions or abnormal drug reactions to the study drug or any of its excipients;
9. Patients who have regularly taken Yangxinshi tablets and similar traditional Chinese medicine, Chinese patent medicine or traditional Chinese medicine decoction with the same curative effectin the past month;
10. Patients who have participated in other clinical drug trials within the last three months;
11. Patients with malignant tumors and other pathological conditions with an expected survival of less than 3 years;
12. Patients whom the investigator deems unsuitable for participating in the clinical trial.

Minimum Eligible Age

40 Years

Maximum Eligible Age

80 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Locations

Explore where the study is taking place and check the recruitment status at each participating site.